Agilent Announces Higher-Sensitivity XF Analysis Solution for Low Abundant Immune Cell Metabolic Analysis
Agilent Technologies Inc. (NYSE: A) has launched the Seahorse XF HS Mini Analyzer, enhancing metabolic analysis capabilities for researchers using rare and genetically engineered cells. This new device offers improved sensitivity and requires fewer cells per well, making it ideal for low respiring cell types like immune cells. As researchers focus on complex in vivo settings, the XF HS Mini promises to unlock advanced metabolic analyses, thereby increasing the utility of Agilent’s technology in disease modeling.
- Launch of the Seahorse XF HS Mini Analyzer enhances metabolic analysis capabilities.
- Improved sensitivity allows analysis of rare and low-respiring cell types.
- Requires fewer cells per well, enabling more comprehensive disease modeling.
- None.
Agilent Technologies Inc. (NYSE: A) today introduced the Agilent Seahorse XF HS Miniplate designed specifically for the Agilent Seahorse XF HS Mini Analyzer for improved immune cell metabolic analysis.
Immunology and disease researchers are increasingly using rare, ex vivo, and genetically engineered cells to build better disease models. Limitations in the quantities of these cells that they can produce, however, restrict these researchers in the types of cellular assays they can perform.
The XF HS Mini is the latest addition to Agilent’s range of Seahorse XF platforms, which analyze mitochondrial respiration, glycolysis, and ATP production in live cells, in real-time. These metabolic measurements enable researchers to better understand cell health, function, and signaling.
The highly sensitive XF HS Mini analyzer offers improved performance and precision, requiring fewer cells per well, an improved more consistent suspension cell workflow, and streamlined analytics. These improvements enable researchers to confidently generate XF data from quantity limited or low respiring cell types, such as immune cells, where measurements were previously not possible.
“Our cells are highly manipulated immune cells which are short-lived, costly, and labor-intensive to generate. Obtaining higher-sensitivity with fewer cell numbers is the ‘make or break’ that enables us to use Agilent’s Seahorse XF technology in our disease model,” stated Katja Weinacht, M.D., Ph.D., assistant professor of Pediatrics in the Division of Stem Cell Transplantation and Regenerative Medicine at Stanford University.
“As our customers strive to unlock biology in more complex and specialized in vivo settings, the need to interrogate rarer cell populations has become evident,” stated David Ferrick, Ph.D., senior director of Agilent's Cell Analysis Division. “The improved sensitivity and precision of the XF HS Mini will open up this new world of metabolic analysis for these customers.”
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005173/en/
FAQ
What is the new product introduced by Agilent Technologies Inc.?
How does the Seahorse XF HS Mini Analyzer benefit researchers?
What cells can be analyzed with the new Seahorse XF HS Mini?
When was the Seahorse XF HS Mini Analyzer launched?
